Exagen Quote - XGN

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

4.15

Bid

3.52

Ask

4.15

Volume

238,603

3.86 Day's Range 4.1768

1.3003 52 Week Range 6.22

Market Cap

73.195M

Previous Close

3.99

Open

3.95

Last Trade

4.15

Last Trade Time

Financial Volume

US$ 955,801

VWAP

4.0058

Average Volume (3m)

156,715

Shares Outstanding

17,637,278

Dividend Yield

PE Ratio

-2.99

Earnings Per Share (EPS)

-1.34

Revenue

52.55M

Net Profit

-23.69M

Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differentia... Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists. Show more

Sector

Medical Laboratories

Industry

Medical Laboratories

Website

www.exagen.com

Headquarters

Wilmington, Delaware, USA

Founded

Exagen Inc is listed in the Medical Laboratories sector of the NASDAQ with ticker XGN. The last closing price for Exagen was US$3.99. Over the last year, Exagen shares have traded in a share price range of US$ 1.3003 to US$ 6.22.

Exagen currently has 17,637,278 shares outstanding. The market capitalization of Exagen is US$70.37 million. Exagen has a price to earnings ratio (PE ratio) of -2.99.

Form 8-K - Current report

Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results

New biomarkers on track for commercial launch in January 2025 Preliminary financial results indicate record full-year revenue and AVISE CTD trailing twelve-month ASP, with improvements to adjusted...

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTD

CARLSBAD, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Exagen Inc., a leading provider of autoimmune testing, today announced the completion of its 1,000,000th AVISE CTD test, marking a significant...

Form 4 - Statement of changes in beneficial ownership of securities

Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform

CARLSBAD, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Exagen Inc., a leading provider of autoimmune testing, today announced the validation and regulatory submission for approval of new Systemic...

Exagen Inc. to Participate in Fourth Quarter Investor Conferences

CARLSBAD, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that management will participate in the...

Exagen Inc. Reports Third Quarter 2024 Results

Expanded AVISE® CTD trailing twelve-month average selling priceReduced Adjusted EBITDA loss for first three quarters of 2024Revenue in line with expectations, excluding one-time adjustments...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	1.07	34.7402597403	3.08	4.2	3.0401	364667	3.99740977	CS
4	-0.85	-17	5	5.195	2.76	222143	3.58179409	CS
12	1.76	73.640167364	2.39	6.22	2.38	156715	4.28756113	CS
26	2.19	111.734693878	1.96	6.22	1.78	96316	3.88576416	CS
52	2.17	109.595959596	1.98	6.22	1.3003	67734	3.30087062	CS
156	-3.7	-47.1337579618	7.85	10.64	1.3003	48948	3.63690639	CS
260	-17.04	-80.4152902312	21.19	26.96	1.3003	47996	8.03193775	CS

XGN - Frequently Asked Questions (FAQ)

What is the current Exagen share price?

The current share price of Exagen is US$ 4.15

How many Exagen shares are in issue?

Exagen has 17,637,278 shares in issue

What is the market cap of Exagen?

The market capitalisation of Exagen is USD 70.37M

What is the 1 year trading range for Exagen share price?

Exagen has traded in the range of US$ 1.3003 to US$ 6.22 during the past year

What is the PE ratio of Exagen?

The price to earnings ratio of Exagen is -2.99

What is the cash to sales ratio of Exagen?

The cash to sales ratio of Exagen is 1.35

What is the reporting currency for Exagen?

Exagen reports financial results in USD

What is the latest annual turnover for Exagen?

The latest annual turnover of Exagen is USD 52.55M

What is the latest annual profit for Exagen?

The latest annual profit of Exagen is USD -23.69M

What is the registered address of Exagen?

The registered address for Exagen is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801

What is the Exagen website address?

The website address for Exagen is www.exagen.com

Which industry sector does Exagen operate in?

Exagen operates in the MEDICAL LABORATORIES sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
NVNINVNI Group Ltd	US$ 4.38 (193.96%)	366.98M
EVAXEvaxion Biotech AS	US$ 5.99 (64.56%)	55.41M
ELABPMGC Holdings Inc	US$ 3.0901 (56.07%)	76.48M
PCLAPicoCELA Inc	US$ 4.60 (49.35%)	3.75M
GOEVCanoo Inc	US$ 0.475 (43.94%)	282.22M
GODNUGolden Star Acquisition Corporation	US$ 3.11 (-75.82%)	17.51k
GODNGolden Star Acquisition Corporation	US$ 2.93 (-65.67%)	902.76k
NXTTNext Technology Holding Inc	US$ 1.37 (-54.93%)	2.56M
SGLYSingularity Future Technology Ltd	US$ 1.625 (-38.45%)	917.77k
WHLRLWheeler Real Estate Investment Trust Inc	US$ 90.11 (-38.07%)	8
ACONAclarion Inc	US$ 0.0557 (28.94%)	811.91M
NVNINVNI Group Ltd	US$ 4.38 (193.96%)	366.98M
RIMEAlgorhythm Holdings Inc	US$ 0.0357 (4.69%)	284.97M
GOEVCanoo Inc	US$ 0.475 (43.94%)	282.22M
NVDANVIDIA Corporation	US$ 142.62 (-3.12%)	232.88M